Comparing and finding new approaches for treating bone loss problem in gum diseases.

Multimodal diagnostic evaluation of the combined efficacy of advanced-platelet rich fibrin and demineralized bone matrix of type one collagen versus their individual assessment in the management of periodontal intrabony defects - a clinico-radiographic and immunological study. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094124

Enrollment

Registered

2025-09-02

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis Health Condition 2: K055- Other periodontal diseases

Interventions

Intervention1: Advanced platelet rich fibrin and xenograft: intervention for 3 6 months Intervention2: Advanced platelet rich fibrin: intervention for 3 6 months Intervention3: Xenograft: intervention

Eligibility

Inclusion criteria

Inclusion criteria: Systemically healthy patients. Presence of intrabony defects with less than or equal to 3mm deep (the distance between the alveolar crest and base of defect) on intraoral periapical radiograph [IOPA]along with interproximal probing depth [PD] less than or equal to 5mm after phase 1 therapy. Patients with no history of allergy to materials and drugs used or prescribed in this study

Exclusion criteria

Exclusion criteria: Patients who have undergone periodontal treatment within a period of 1 year. Patients on any medication taken within the last 6 months which may alter the periodontal status. Chronic smokers and alcoholics. Pregnant and lactating females.

Design outcomes

Primary

Measure	Time frame
The combined efficacy of advanced-platelet rich fibrin and demineralized bone matrix of type one collagen is expected to show better results when compared to the groups where each component is assessed individually.Timepoint: Baseline 3 months 6 months	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Sanjana TS Rao

Rajarajeswari dental college and hospital

senthilrajanrs21@gmail.com9036943516

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026